Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress
11:00am, Monday, 22'nd Aug 2022 GlobeNewswire Inc.
Oral presentation will include data from the Phase 2 trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica Oral presentation will include
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
05:00am, Friday, 19'th Aug 2022 GlobeNewswire Inc.
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
7 Steps to Investing in Marijuana Stocks
07:19pm, Wednesday, 10'th Aug 2022 The Motley Fool
Here are seven steps to investing in the high-flying cannabis industry.
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
09:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics, Inc. (CARA) CEO Christopher Posner on Q2 2021 Results - Earnings Call Transcript
08:44pm, Monday, 08'th Aug 2022
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q2 2021 Results Conference Call August 8, 2022 4:30 PM ET Company Participants Iris Francesconi - Head of Investor Relations Christopher Posner - President and C
Cara Therapeutics Reports Second Quarter 2022 Financial Results
08:01pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?
12:48pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?
10:33am, Thursday, 04'th Aug 2022
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
07:00am, Wednesday, 03'rd Aug 2022
STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022
04:01pm, Monday, 01'st Aug 2022
STAMFORD, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Brazilian Fund Allows People To Invest In US Cannabis Stocks Starting With Just $18.50
04:31pm, Tuesday, 05'th Jul 2022 Benzinga
As scientific research continues to produce studies on the health benefits of cannabis and CBD and legalization of the plant grows across the globe, not unsurprisingly traditional investment firms are
Calls A Much Safer Way To Buy Cara Therapeutics
09:51am, Friday, 24'th Jun 2022
Since I wrote my bullish call on Cara Therapeutics, the shares have absolutely collapsed. I thought I'd revisit the name again to see if I should add, hold, or sell. The company reported earnings, and
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
09:25pm, Monday, 09'th May 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
06:49pm, Monday, 09'th May 2022
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
